COVID-19

The objective of this study was to determine clinical characteristics and outcomes in hospitalised PD individuals infected with COVID-19.

The objective of this study was to determine whether previously identified risk factors for 30-day mortality in Dutch NH residents with COVID-19 are unique to COVID-19.

In this review, the authors summarize possible mechanisms by which infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, may cause AD in elderly COVID-19 patients and describe preventive measures to mitigate risk.

The European Federation of Neurological Associations, in partnership with the NeuroCOVID-19 taskforce of the European Academy of Neurology, has investigated the impact of the first wave of the COVID-19 pandemic on patients with neurological diseases, as well as the hopes and fears of these patients about the post-pandemic phase.

The aims of this study were to analyze the characteristics and outcomes of patients with stroke admitted during the second COVID-19 wave and to evaluate the differences in the stroke care provision compared with the first wave.

The aim of this study was to evaluate whether mortality of patients with CVST-VITT has decreased over time.

In this article the authors review neurological conditions seen in the context of prior vaccinations and the current data to date on select COVID-19 vaccines.

This study describes the perspectives and experiences of community neurologists providing care for patients with neurodegenerative illnesses during the COVID-19 pandemic.

In this study the authors conducted an open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset (NCT04348656).

In this article the authors investigated induction of antigen-specific antibody, B cell and T cell responses longitudinally in patients with multiple sclerosis (MS) on anti-CD20 antibody monotherapy (n = 20) compared with healthy controls (n = 10) after BNT162b2 or mRNA-1273 mRNA vaccination.

The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is an unprecedented global health crisis. However, therapeutic options for treatment are still very limited.

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel spike protein mutations that are influencing the epidemiological and clinical aspects of the COVID-19 pandemic.

The objective of this study was to derive and validate risk prediction algorithms to estimate the risk of COVID-19 related mortality and hospital admission in UK adults after one or two doses of COVID-19 vaccination.

The objective of this systematic review was to summarize the descriptive epidemiology and clinical characteristics of MIS-A.

This study evaluates the efficacy and safety of baricitinib in combination with standard of care for the treatment of hospitalised adults with COVID-19.